This phase 2 trial shows LEN‑TAP (lenvatinib+TACE+PD‑1) improves resection, response, and survival in unresectable #HepatocellularCarcinoma vs. #TACE alone, with HLA‑DR⁺CD38⁺CD8⁺ T cells emerging as #biomarkers of therapeutic benefit.
#OpenAccess in #STTT: doi.org/10.1038/s413...